M. Benjamin Shoemaker

Has grant

Assistant Professor

Vanderbilt University Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Atrial Fibrillation Susceptibility due to Common Genetic Variation at Chromosome 4q25

Open Date: 2015-04-01

Close Date: 2020-03-01

Articles (4)

Background Genetic testing is now recommended for select patients with early-onset atrial fibrillation (AF). Hemochromatosis is an autosomal recessive syndrome that occurs in patients who carry two pathogenic or likely-pathogenic (P/LP) variants in HFE. HFE is included on some genetic testing panels used for patients with AF. Hemochromatosis causes cardiomyopathy due to iron overload in the ventricle; however, it is unknown whether AF can be an early manifestation that is identified by genetic testing. Methods A total of 347 patients were referred to a dedicated AF precision medicine clinic. The clinical diagnostic evaluation included an H&P, 12-lead ECG, ambulatory ECG monitoring, and cardiac imaging (cardiac MRI and/or TTE). Genetic testing was performed using CLIA-approved laboratories: Labcorp/Invitae, GeneDx, or Vanderbilt University Medical Center. HFE was included on the cardiomyopathy panel used by 2 of the 3 laboratories. Results HFE was tested in 165 participants (median age 46 years [IQR 35-55], 115 [70%] male, 149 [90%] White). Six participants (4%) had two pathogenic variants in HFE. All of them were C282Y/H63D compound heterozygotes. Forty-one participants (25%) were heterozygous carriers of one pathogenic HFE variant. Among the 6 participants with 2 pathogenic HFE variants, the median ferritin level was 346 mcg/L [IQR 262, 496] (normal 11.4 ms; liver iron concentration 3.4 mg/g, normal <2 mg/g). Three out of 6 participants were referred for a hematology evaluation and 2 out of 6 were started on therapeutic phlebotomy. Conclusion Genetic testing can identify patients with early-onset AF who are genetically susceptible to hemochromatosis, have evidence of iron overload, and receive early intervention with therapeutic phlebotomy. These results suggest HFE should be sequenced as part of genetic testing for early-onset AF, but larger sample sizes are needed to confirm these results.

Year:

2026

Background and Aims Genetic testing is recommended for select patients with atrial fibrillation (AF). The aims of this study were to define the results of genetic evaluation and its therapeutic impact for patients referred to a dedicated AF precision medicine clinic. Methods Patients diagnosed with AF before age 60 were candidates for referral. In addition to standard evaluation with history, physical exam, and ECG, genetic evaluation included a 3-generation pedigree, cardiac imaging, ambulatory monitoring, and clinical genetic testing with a cardiomyopathy/arrhythmia panel. Results 264 participants were referred: the median age was 47 years (Q1, Q3: 38, 55), 77 (29%) were female, and 236 (89%) were White. Median age at AF diagnosis was 39 years (Q1, Q3: 31, 48) and median time from AF diagnosis to evaluation was 3.7 years (Q1, Q3: 0.9, 10). 242 patients (92%) underwent genetic testing, which identified a pathogenic or likely pathogenic variant in 48 (20%). The strongest predictors of positive genetic testing were history of cardiomyopathy, infranodal conduction disease, and elevated T1 or late gadolinium enhancement on cardiac MRI (all p<0.05). The strongest predictors of negative genetic testing were obstructive sleep apnea and a normal 12-lead ECG (both p<0.04). Overall, genetic testing changed clinical management in 52% of patients with positive genetic testing, highlighted by 7 new ICD placements and initiation of disease modifying therapy in 16 patients. Conclusions Genetic testing was positive in 20% of patients with early-onset AF referred to a dedicated AF precision medicine clinic. Genetic testing results changed clinical management in approximately half of genotype-positive patients. STRUCTURED GRAPHICAL ABSTRACT Key Question Does genetic evaluation of patients with early-onset atrial fibrillation (AF) change their clinical management? Key Finding Among 246 participants that completed genetic evaluation in a dedicated AF precision medicine clinic, 20% had positive genetic testing with identification of a pathogenic cardiomyopathy or channelopathy variant. These findings led to changes in clinical management in 52% of patients with positive genetic testing. Take-home Message Genetic evaluation of patients with early-onset AF consists of detailed phenotyping and genetic testing to identify previously undiagnosed genetic disorders. This facilitates earlier diagnosis and clinical intervention.

Year:

2025

Background KCNQ1 loss of function variants are thought to cause type 1 long QT syndrome by reducing I Ks . However, we have recently reported that pharmacologic block of I Ks in human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) produced minimal increases in action potential duration at 90% repolarization (APD 90 ), while genetic loss of KCNQ1 markedly prolonged APD 90 . We sought here to define mechanisms underlying APD prolongation by genetic loss of KCNQ1 . Methods We studied iPSC-CMs from population controls, an isogenic KCNQ1 knock out (KO) line created by a homozygous edit for the R518X loss of function variant, and 2 unrelated patients with the Jervell and Lange-Nielsen syndrome (JLN) due to compound heterozygosity for loss of function KCNQ1 variants. Results In both JLN and the KCNQ1-KO lines, I Ks was absent, APD 90 was markedly prolonged, and L-type Ca channel (LTCC) current ( I Ca-L ) was significantly increased, 2-3-fold, compared to the control cells with no change in kinetics or gating. RNA-sequencing identified 298 and 584 genes that were up– and down-regulated, respectively, by KCNQ1-KO compared to the isogenic control cells. Gene ontology analysis identified down-regulation of 6 Ca 2+ channel negative regulatory genes (p=0.0002, FDR=0.02), and in knockdown experiments in wild-type iPSC-CMs, three of these, CBARP , FKBP1B , and RRAD , increased I Ca-L , and RRAD increased APD 90 . A therapeutic low concentration (1 μM) of the Ca channel antagonist diltiazem significantly shortened APD 90 in the two JLN cell lines and in KCNQ1-KO cells. A single low dose of intravenous diltiazem in one of the JLN patients shortened QTc. Conclusions These data further support the concept that delayed repolarization in JLN cannot be explained solely by loss of I Ks . Our findings demonstrate that KCNQ1 mutations lead to down-regulation of Ca 2+ channel inhibitory genes, with resultant increased I Ca-L that underlies delayed repolarization in JLN. We further propose that diltiazem can be repurposed for treatment of patients with JLN.

Year:

2025

Background Recurrence after atrial fibrillation (AF) ablation remains common. We evaluated the association between recurrence and levels of biomarkers of cardiac remodeling, and their ability to improve recurrence prediction when added to a clinical prediction model. Methods and Results Blood samples collected before de novo catheter ablation were analyzed. Levels of bone morphogenetic protein‐10, angiopoietin‐2, fibroblast growth factor‐23, insulin‐like growth factor‐binding protein‐7, myosin‐binding protein C3, growth differentiation factor‐15, interleukin‐6, N‐terminal pro‐brain natriuretic peptide, and high‐sensitivity troponin T were measured. Recurrence was defined as ≥30 seconds of an atrial arrhythmia 3 to 12 months postablation. Multivariable logistic regression was performed using biomarker levels along with clinical covariates: APPLE score (Age >65 years, Persistent AF, imPaired eGFR [<60 ml/min/1.73m 2 ], LA diameter ≥43 mm, EF <50%; which includes age, left atrial diameter, left ventricular ejection fraction, persistent atrial fibrillation, and estimated glomerular filtration rate), preablation rhythm, sex, height, body mass index, presence of an implanted continuous monitor, year of ablation, and additional linear ablation. A total of 1873 participants were included. A multivariable logistic regression showed an association between recurrence and levels of angiopoietin‐2 (odds ratio, 1.08 [95% CI, 1.02–1.15], P =0.007) and interleukin‐6 (odds ratio, 1.02 [95% CI, 1.003–1.03]; P =0.02). The area under the receiver operating characteristic curve of a model that only contained clinical predictors was 0.711. The addition of any of the 9 studied biomarkers to the predictive model did not result in a statistically significant improvement in the area under the receiver operating characteristic curve. Conclusions Higher angiopoietin‐2 and interleukin‐6 levels were associated with recurrence after atrial fibrillation ablation in multivariable modeling. However, the addition of biomarkers to a clinical prediction model did not significantly improve recurrence prediction.

Year:

2024

Collaborators (5)

Zachary Yoneda

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Dan M Roden

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Bjorn Knollmann

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Yuko Wada

-

UNITED STATES
View details

Prince Kannankeril

Professor

Vanderbilt University Medical Center

UNITED STATES
View details